<DOC>
	<DOCNO>NCT00163748</DOCNO>
	<brief_summary>This open label pilot study 40 evaluable patient receive vinorelbine-gemcitabine combination chemotherapy filgrastim support outpatient set . Participating patient time registration measurable relapsed primary refractory lymphoma .</brief_summary>
	<brief_title>Efficacy Treatment Related Toxicity Study New Regimen Lymphoma</brief_title>
	<detailed_description>Patients suffer lymphoma ( type cancer white blood cell call lymphocyte ) less chance cure refractory initial chemotherapy relapse receive initial chemotherapy compare patient responsive relapse follow initial chemotherapy . The standard care , therefore , patient undergo form bone marrow transplant procedure . However , consider patient require chemotherapy control lymphoma determine whether lymphoma still sensitive alternative type chemotherapy ( salvage chemotherapy ) . Currently use type salvage chemotherapy require significant period inpatient hospitalisation associate significant haematological toxicity ( low blood count associated risk infection bleed need blood platelet transfusion ) . Two new chemotherapy drug , vinorelbine gemcitabine , show encouraging efficacy lymphoma use alone patient heavily pretreated lymphoma . Furthermore , give outpatient set usually associate significant haematological toxicity . All patient participate study diagnose relapsed refractory lymphoma offer treatment vinorelbine gemcitabine alternative inpatient salvage chemotherapy .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<criteria>age 18 70 year relapse primary refractory nonHodgkin 's lymphoma ( NHL ) Hodgkin 's Disease ( HD ) measurable disease ( clinically radiologically ) ECOG 0 2 write informed consent Exclusion criterion : bilirubin &gt; 50Î¼mol/litre unless secondary lymphoma creatinine &gt; 2 x upper limit normal unless secondary lymphoma , absolute neutrophil count &lt; 0.5 x 109/litre / platelet &lt; 50 x 109/litre unless secondary lymphoma isolate bone marrow disease know sensitivity E coli derive preparation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Lymphoma</keyword>
</DOC>